Liquidia is a biopharmaceutical company focused on the development, manufacturing and commercialization of products with focus directed towards the treatment of pulmonary hypertension (PH). Co. conducts research and manufacturing of products by applying its proprietary PRINT® technology, a particle engineering platform. Co.'s products and candidates for PH include: YUTREPIATM (treprostinil) Inhalation Powder to Treat PAH, which is an inhaled dry powder formulation of treprostinil; and Treprostinil Injection, a Generic Version of Remodulin®, which contains the same active ingredient, same strength, same dosage forms and same inactive ingredient amounts as Remodulin®. The LQDA stock yearly return is shown above.
The yearly return on the LQDA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LQDA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|